The role of oxidative stress in prostate cancer

European Journal of Cancer Prevention

Volumn 21, Issue 2, 2012, Pages 155-162

  Gupta Elera, Gaytri ^a   Garrett, Andrew R ^a   Robison, Richard A ^a   O'Neill, Kim L ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Antioxidants; Oxidative stress; Prevention; Prostate cancer; Reactive oxygen species

Indexed keywords

ANDROGEN; CAROTENOID; DOCETAXEL; GENISTEIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; LYCOPENE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; RAPAMYCIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELENITE; STAUROSPORINE; VITAMIN D;

ADENOCARCINOMA; AGING; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; BLADDER METASTASIS; BLOOD TESTIS BARRIER; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DIGITAL RECTAL EXAMINATION; DNA DAMAGE; HUMAN; HYPOXIA; INFERTILITY; LYMPH NODE METASTASIS; METASTASIS; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; RECTAL METASTASIS; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SPERM; TUMOR BIOPSY;

ADENOCARCINOMA; CELL AGING; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; OXIDATIVE STRESS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84858293788     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834a8002     Document Type: Review

References (58)

1. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000). Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852.
2. Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA, Buttyan R (2003). Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy. Current Drug Targets 4:191-196. (Pubitemid 36367617)
3. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, et al. (2009). Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 42:1228-1235.
4. Aydin A, Eken A, Erdem O, Arsova-Sarafinovska Z, Sayal A, Dimovski A, et al. (2009). Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Toxicol Lett 189:S132-S132.
5. Bataller M, Portugal J (2005). Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells. Arch Biochem Biophys 437:151-158. (Pubitemid 40585817)
6. Borgermann C, vom Dorp F, Breuer G, Kliner S, Rubben H (2010). Early detection of prostate cancer: is serum PSA testing alone sufficient? Urologe A 49:1351-1355.
7. Bostwick D (2000). Prostatic intraepithelial neoplasia. Current Urology Reports 1:65-70.
8. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (New York, NY) 251:802.
9. 2: relevance to redox signalling in apoptosis. Free Radical Res 39:S16-S16.
10. Chang S, Erdman JW, Clinton SK, Vadiveloo M, Strom SS, Yamamura Y, et al. (2005). Relationship between plasma carotenoids and prostate cancer. Nutrition and Cancer 53:127.
11. Cheema U, Alekseeva T, Abou-Neel EA, Brown RA (2010). Switching off angiogenic signalling: creating channelled constructs for adequate oxygen delivery in tissue engeneered constructs. Eur Cells Materials 20:274-281.
12. Cheung E, Wadhera P, Dorff T, Pinski J (2008). Diet and prostate cancer risk reduction. Exp Rev Anticancer Therap 8:43-50.
13. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, et al. (2005). Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. The Prostate 63:155-168. (Pubitemid 40525365)
14. Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO (2010). Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med 12:755-765.
15. Drew BL (2002). Aging and the role of reactive nitrogen species. Annals of the New York Academy of Sciences 959:66-81.
16. Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM (2010). Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomark Prevent 19:2437-2444.
17. Frohlich DA, McCabe MT, Arnold RS, Day ML (2008). The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 27:4353-4362. (Pubitemid 352010007)
18. Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, et al. (2003). Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 54:58-67. (Pubitemid 36043837)
19. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1995). Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87:1767-1776.
20. Haddad JJ (2004). Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno- pharmaco- redox conception of oxidative siege versus cell death commitment. International Immunopharmacology 4:475-493.
21. Harman D (2006). Free radical theory of aging: an update increasing the functional life span. In: Rattan S, Kristensen P, Clark BFC, editors. Understanding and modulating aging. pp. 10-21.
22. Hayes JD, Pulford DJ (2003). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445.
23. Hendrickson WK, Julie L, Flavin R, Fiorentino M, Lis R, Fiore C, Penney K (2010). Vitamin D receptor expression is inversely associated with prostate cancer progression. Cancer Prev Res 3 (Suppl 1).
24. Heymach JV, Terrry JS, Tran H, Yoo S-Y, Do K-A, Wergin M, Saintigny P (2010). Low-fat diet reduces NF-{kappa}B regulated inflammatory cytokines and angiogenic factors in plasma of men with prostate cancer. Cancer Prev Res 3 (Suppl 2).
25. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. (2008). ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (New York, NY) 320:661-664. (Pubitemid 351928347)
26. Jain A, Lamark T, Sjottem E, Larsen KB, Awuh JA, Overvatn A, et al. (2010). p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285:22576-22591.
27. Jemal A, Siegel R, Xu JQ, Ward E (2010). Cancer statistics, 2010. Cancer Journal for Clinicians 60:277-300.
28. Kim H-S, Bowen P, Chen L, Duncan C, Ghosh L, Sharifi R, et al. (2003). Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutrition and Cancer 47:40-47. (Pubitemid 38250434)
29. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, et al. (2006). A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomark Prev 15:92-98.
30. Kong Q, Beel JA, Lillehei KO (2000). A threshold concept for cancer therapy. Medical Hypotheses 55:29-35. (Pubitemid 30612080)
31. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008). Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68:1777.
32. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JMO, et al. (2005). Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA: the Journal of the American Medical Association 293:1338-1347. (Pubitemid 40381486)
33. Lu CC, Yang JS, Huang AC, Hsia TC, Chou ST, Kuo CL, et al. (2010). Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells. Mol Nut Food Res 54:967-976.
34. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G (2008). JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate 68:924-934. (Pubitemid 351794157)
35. Mehraein-Ghomi FB, Basu HS, Church D, Hoffmann M, Wilding G (2010). Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res 70:4560-4568.
36. Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G, Finazzi-Agro A (1997). S-nitrosylation regulates apoptosis. Nature 388:432-433.
37. Miner M, Rosenberg MT, Perelman MA (2006). Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clinical Therapeutics 28:13-25. (Pubitemid 43254986)
38. Miyoshi N, Oubrahim H, Chock PB, Stadtman ER (2006). Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Nat Acad Sci USA 103:1727-1731. (Pubitemid 43228761)
39. Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, Tang DL, et al. (2009). Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control 20:1915-1926.
40. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C (2005). Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65:6773-6779. (Pubitemid 41060715)
41. Pannellini TI, Lezzi M, Liberatore M (2010). A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res 3:1284-1291.
42. Potts JM, Pasqualotto FF (2003). Seminal oxidative stress in patients with chronic prostatitis. Andrologia 35:304-308. (Pubitemid 37363522)
43. Rohrmann S, Genkinger JM, Burke A, Helzlsouer KJ, Comstock GW, Alberg AJ, et al. (2007). Smoking and risk of fatal prostate cancer in a prospective US study. Urology 69:721-725. (Pubitemid 46574914)
44. Singh RK, Lokeshwar BL (2009). Depletion of intrinsic expression of interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8:15.
45. Society American Cancer. 2010 What are the key statistics about prostate cancer? [cited; available from: http://www.cancer.org/Cancer/ProstateCancer/ DetailedGuide/prostate-cancer-key-statistics].
46. Surapaneni KM, Venkata GR (2006). Lipid peroxidation and antioxidant status in patients with carcinoma of prostate. Indian J Physiol Pharmacol 50:350.
47. Terraneo L, Bianciardi P, Caretti A, Ronchi R, Samaja M (2010). Chronic systemic hypoxia promotes LNCaP prostate cancer growth in vivo. Prostate 70:1243-1254.
48. Tong X, Li H (2004). eNOS protects prostate cancer cells from TRAIL induced apoptosis. Cancer Lett 210:63-71. (Pubitemid 38692589)
49. Trion A, Van Hengel-Zonruiter D, Reneman S, De Ridder CMA, Schalch W, Van Weerden WM (2007). Combined treatment with lycopene and vitamin E. What is the optimal dose for inhibition of prostate cancer development in nude mice? BJU Int 100:41-42.
50. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Härkönen P (2001). Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:25-28. (Pubitemid 32216724)
51. Vaupel P (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198-206.
52. Villena J, Henriquez M, Torres V, Moraga F, Diaz-Elizondo J, Arredondo C, et al. (2008). Ceramide-induced formation of ROS and ATP depletion trigger necrosis in lymphoid cells. Free Radical Biol Med 44:1146-1160.
53. Wu K, Erdman JW, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, et al. (2004). Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol, Biomarkers Prev 13:260-269. (Pubitemid 38222558)
54. Yu YP, Yu GY, Tseng G, Cieply K, Nelson J, Defrances M, et al. (2007). Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 67:8043-8050. (Pubitemid 47395138)
55. Zhao R, Xiang N, Domann FE, Zhong WX (2009). Effects of selenite and genistein on G(2)/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr Cancer 61:397-407.
56. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835.
57. Zhong H, Semenza GL, Simons JW, De Marzo AM (2004). Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28:88-93. (Pubitemid 38448745)
58. Zolochevska O, Figueiredo M (2009). Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanisms. Oral Oncology 45:106-112.